-
2024-09-23
优锐医药与Altamira Therapeutics签署独家协议,在部分东亚与东南亚市场开发和经销百畅悠(Bentrio)鼻喷剂
优锐医药今日宣布与Altamira Medica Ltd.签署独家协议,授权优锐在部分东亚及东南亚市场开发和商业化百畅悠(Bentrio)鼻喷剂。
-
2024-09-23
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
Altamira Medica Ltd. has agreed with its partner Nuance Pharma to extend the territory covered by their exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
-
2024-09-11
优锐医药宣布完成恩司芬群用于维持治疗COPD的中国三期临床研究患者招募
优锐医药宣布完成恩司芬群(Ohtuvayre™)的ENHANCE-CHINA中国三期临床研究的患者招募,计划数量的患者全部成功入组。
-
2024-08-14
优锐医药创始人兼首席执行官Mark Lotter接受PharmaBoardroom采访
-
2024-06-27
美国食品和药品监督管理局(FDA)批准Ohtuvayre™ (恩塞芬汀)用于维持治疗COPD的新药上市许可申请
优锐医药合作伙伴Verona Pharma plc (Nasdaq: VRNA)宣布,美国食品药品监督管理局("FDA")已批准Ohtuvayre(恩塞芬汀)用于维持治疗中重度慢性阻塞性肺病("COPD")患者的新药上市许可申请。
-
2024-06-27
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Verona Pharma plc (Nasdaq: VRNA) announces the US Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD
-
2024-03-12
优锐医药出席第三届BioCentury East-West 新加坡医疗峰会
- 1